About PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PTCT
- CUSIP: N/A
- Web: www.ptcbio.com
- Market Cap: $728.78 million
- Outstanding Shares: 41,304,000
- 50 Day Moving Avg: $19.24
- 200 Day Moving Avg: $16.77
- 52 Week Range: $4.03 - $22.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.03
- P/E Growth: 0.79
- Annual Revenue: $122.69 million
- Price / Sales: 5.99
- Book Value: $4.11 per share
- Price / Book: 4.33
- EBITDA: ($90,430,000.00)
- Net Margins: -88.43%
- Return on Equity: -81.84%
- Return on Assets: -36.49%
- Debt-to-Equity Ratio: 0.83%
- Current Ratio: 3.34%
- Quick Ratio: 3.24%
- Average Volume: 1.00 million shs.
- Beta: 1.37
- Short Ratio: 12
Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.45. The business had revenue of $47.96 million for the quarter, compared to analyst estimates of $28.78 million. PTC Therapeutics had a negative return on equity of 81.84% and a negative net margin of 88.43%. The firm's revenue for the quarter was up 206.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.14) earnings per share. View PTC Therapeutics' Earnings History.
When will PTC Therapeutics make its next earnings announcement?
Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?
9 brokers have issued 1-year price targets for PTC Therapeutics' stock. Their predictions range from $7.00 to $28.00. On average, they expect PTC Therapeutics' share price to reach $16.38 in the next year. View Analyst Ratings for PTC Therapeutics.
What are analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (10/11/2017)
- 2. Cowen and Company analysts commented, "PTCT announced 4Q16 results today: Translarna EU sales continue to grow." (3/16/2017)
- 3. Royal Bank Of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
- 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include Acceleron Pharma (XLRN), MyoKardia (MYOK), Five Prime Therapeutics (FPRX), AnaptysBio (ANAB), Clinigen Group PLC (CLIN), Acorda Therapeutics (ACOR), Dynavax Technologies Corporation (DVAX), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Sangamo Therapeutics (SGMO), Epizyme (EPZM), Ascendis Pharma A/S (ASND), NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Athenex (ATNX), Ignyta (RXDX) and Retrophin (RTRX).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Michael Schmertzler, Independent Chairman of the Board
- Stuart W. Peltz Ph.D., Chief Executive Officer, Director
- Christine Marie Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer
- Marcio Souza, Chief Operating Officer
- Mark E. Boulding, Executive Vice President, Chief Legal Officer and Corporate Secretary
- Neil Almstead Ph.D., Executive Vice President, Research, Pharmaceutical Operations & Technology
- Tuyen Ong, Chief Medical Officer
- Allan S. Jacobson Ph.D., Independent Director
- David P. Southwell, Independent Director
- Glenn D. Steele Jr., M.D., Ph.D., Independent Director
Who owns PTC Therapeutics stock?
PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.42%). Company insiders that own PTC Therapeutics stock include Dawn Svoronos, Mark Rothera and Neil Gregory Almstead. View Institutional Ownership Trends for PTC Therapeutics.
Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?
PTC Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.
How do I buy PTC Therapeutics stock?
Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of PTC Therapeutics stock can currently be purchased for approximately $17.79.
Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.11)|
|Consensus Price Target: ||$16.38 (7.95% downside)|Consensus Price Target History for PTC Therapeutics (NASDAQ:PTCT)
Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/9/2017||J P Morgan Chase & Co||Downgrade||Neutral -> Underweight||$23.00 -> $15.00||N/A|
|9/29/2017||Royal Bank Of Canada||Reiterated Rating||Sector Perform -> Sector Perform||High|
|9/29/2017||Barclays PLC||Lower Price Target||Equal Weight -> Equal Weight||$22.00 -> $15.00||High|
|9/27/2017||Citigroup Inc.||Reiterated Rating||Buy||$28.00||Low|
|9/26/2017||Credit Suisse Group||Reiterated Rating||Outperform||$25.00||High|
|8/23/2017||William Blair||Initiated Coverage||Mkt Perform -> Market Perform||$17.00||Low|
|3/16/2017||Cowen and Company||Reiterated Rating||Hold||High|
|1/10/2017||Jefferies Group LLC||Reiterated Rating||Hold||$12.00||N/A|
|11/11/2016||Wedbush||Reiterated Rating||Neutral||$12.00 -> $7.00||N/A|
|10/3/2016||Bank of America Corporation||Reiterated Rating||Hold||$15.00||N/A|
|4/17/2016||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$39.00||N/A|
Earnings History for PTC Therapeutics (NASDAQ:PTCT)Earnings History by Quarter for PTC Therapeutics (NASDAQ PTCT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.89)||($0.44)||$28.78 million||$47.96 million||View||Listen|
|5/8/2017||Q1 2017||($0.88)||($0.85)||$27.93 million||$26.50 million||View||Listen|
|3/16/2017||12/31/2016||($1.07)||($0.78)||$24.69 million||$25.20 million||View||N/A|
|11/2/2016||Q316||($1.22)||($1.03)||$19.76 million||$23.00 million||View||N/A|
|8/4/2016||Q216||($1.27)||($1.14)||$15.24 million||$15.40 million||View||N/A|
|5/5/2016||Q116||($1.26)||($1.22)||$13.74 million||$18.90 million||View||N/A|
|2/29/2016||Q415||($1.25)||($1.50)||$13.04 million||$12.70 million||View||Listen|
|11/9/2015||Q315||($1.15)||($1.27)||$9.88 million||$9.78 million||View||Listen|
|7/30/2015||Q215||($1.20)||($1.14)||$7.73 million||$6.77 million||View||Listen|
|5/4/2015||Q115||($1.20)||($1.15)||$2.97 million||$7.50 million||View||N/A|
|2/27/2015||Q414||($0.83)||($0.84)||$7.99 million||$12.70 million||View||Listen|
|11/6/2014||Q314||($0.90)||($0.93)||$1.76 million||$1.69 million||View||N/A|
|8/7/2014||Q214||($0.75)||($0.86)||$1.71 million||$1.70 million||View||N/A|
|5/6/2014||($0.46)||($0.58)||$10.93 million||$9.22 million||View||N/A|
|3/6/2014||Q413||($0.57)||($0.75)||$6.15 million||$4.40 million||View||N/A|
|11/14/2013||Q3||($0.29)||($0.19)||$7.20 million||$16.29 million||View||Listen|
Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
2017 EPS Consensus Estimate: ($2.87)
2018 EPS Consensus Estimate: ($2.36)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 8.10%Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership Percentage: 81.30%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/23/2017||Dawn Svoronos||Director||Buy||25,000||$13.49||$337,250.00|| |
|1/5/2017||Neil Gregory Almstead||EVP||Sell||78||$11.82||$921.96|| |
|3/3/2016||Mark Rothera||Insider||Buy||2,000||$6.23||$12,460.00|| |
|7/6/2015||David P Southwell||Director||Sell||23,604||$47.52||$1,121,662.08|| |
|6/18/2015||Allan Steven Jacobson||Director||Sell||5,000||$50.13||$250,650.00|| |
|6/9/2015||Stuart Walter Peltz||CEO||Sell||100,000||$54.49||$5,449,000.00|| |
|6/8/2015||Mark Elliott Boulding||VP||Sell||56,849||$55.04||$3,128,968.96|| |
|6/8/2015||Richard Aldrich||Director||Sell||7,000||$55.66||$389,620.00|| |
|6/8/2015||Stuart Walter Peltz||CEO||Sell||73,700||$54.91||$4,046,867.00|| |
|5/22/2015||Shane William Charles Kovacs||CFO||Sell||82,491||$55.41||$4,570,826.31|| |
|4/15/2015||Neil Gregory Almstead||EVP||Sell||9,511||$68.65||$652,930.15|| |
|3/23/2015||David P Southwell||Director||Sell||2,317||$69.04||$159,965.68|| |
|3/23/2015||Stuart Walter Peltz||CEO||Sell||47,200||$69.14||$3,263,408.00|| |
|3/20/2015||Mark Elliott Boulding||VP||Sell||21,142||$68.12||$1,440,193.04|| |
|3/18/2015||Allan Steven Jacobson||Director||Sell||16,616||$76.00||$1,262,816.00|| |
|3/17/2015||Mark Rothera||Insider||Sell||10,700||$76.64||$820,048.00|| |
|3/16/2015||Michael L Kranda||Director||Sell||2,500||$72.81||$182,025.00|| |
|3/13/2015||Robert J Spiegel||Insider||Sell||1,030||$75.10||$77,353.00|| |
|3/10/2015||Neil Gregory Almstead||EVP||Sell||79||$70.71||$5,586.09|| |
|3/9/2015||Stuart Walter Peltz||CEO||Sell||47,201||$70.74||$3,338,998.74|| |
|2/25/2015||Mark Rothera||Insider||Sell||35,000||$68.01||$2,380,350.00|| |
|2/24/2015||Mark Rothera||Insider||Sell||1,000||$67.70||$67,700.00|| |
|2/23/2015||Mark Rothera||Insider||Sell||23,000||$65.40||$1,504,200.00|| |
|1/21/2015||Neil Gregory Almstead||EVP||Sell||26,096||$60.26||$1,572,544.96|| |
|1/20/2015||Mark Rothera||Insider||Sell||3,000||$60.02||$180,060.00|| |
|1/16/2015||Mark Rothera||Insider||Sell||2,300||$58.67||$134,941.00|| |
|1/15/2015||Claudia De Oliveira Ri Hirawat||President||Sell||2,149||$57.19||$122,901.31|| |
|1/14/2015||Mark Rothera||Insider||Sell||9,700||$58.04||$562,988.00|| |
|12/15/2014||Claudia De Oliveira Ri Hirawat||President||Sell||2,173||$55.24||$120,036.52|| |
|11/17/2014||Claudia De Oliveira Ri Hirawat||President||Sell||2,173||$39.78||$86,441.94|| |
|10/15/2014||Claudia De Oliveira Ri Hirawat||President||Sell||45,661||$36.15||$1,650,645.15|| |
|10/10/2014||Claudia De Oliveira Ri Hirawat||President||Sell||43,489||$36.18||$1,573,432.02|| |
|10/1/2014||Stuart Walter Peltz||CEO||Sell||41,501||$42.65||$1,770,017.65|| |
|9/26/2014||Mark Rothera||Insider||Sell||16,000||$44.63||$714,080.00|| |
|9/18/2014||Allan Steven Jacobson||Director||Sell||2,000||$40.16||$80,320.00|| |
|9/15/2014||Mark Rothera||Insider||Sell||8,000||$36.24||$289,920.00|| |
|5/22/2014||Shane William Charles Kovacs||CFO||Sell||1,650||$14.74||$24,321.00|| |
|3/24/2014||Stuart Walter Peltz||CEO||Sell||25,487||$29.86||$761,041.82|| |
|3/21/2014||Claudia De Oliveira Ri Hirawat||President||Sell||15,320||$29.61||$453,625.20|| |
|3/21/2014||David Southwell||Director||Sell||2,317||$30.93||$71,664.81|| |
|3/20/2014||Mark Elliott Boulding||VP||Sell||10,049||$30.96||$311,117.04|| |
|3/19/2014||Neil Gregory Almstead||VP||Sell||10,859||$31.91||$346,510.69|| |
|3/18/2014||Allan Steven Jacobson||Director||Sell||7,616||$31.18||$237,466.88|| |
|3/14/2014||Michael Kranda||Director||Sell||1,186||$31.02||$36,789.72|| |
|3/13/2014||Robert Spiegel||Insider||Sell||1,186||$31.75||$37,655.50|| |
|3/7/2014||Stuart Walter Peltz||CEO||Sell||27,414||$29.91||$819,952.74|| |
|12/17/2013||Hbm Healthcare Investments (Ca||major shareholder||Sell||66,667||$19.08||$1,272,006.36|| |
|6/25/2013||Adam Koppel||Director||Buy||1,250,000||$15.00||$18,750,000.00|| |
|6/25/2013||Hbm Healthcare Investments (Ca||Major Shareholder||Buy||666,676||$15.00||$10,000,140.00|| |
|6/25/2013||Mark Rothera||Insider||Buy||25,000||$15.00||$375,000.00|| |
Headline Trends for PTC Therapeutics (NASDAQ:PTCT)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
Loading headlines, please wait.
PTC Therapeutics (PTCT) Chart for Saturday, October, 21, 2017